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rectal cancer (CRC) after controlling for other risk factors. METHODS: We identified a 
cohort of 37,044 elderly Medicare beneficiaries with incident CRC between 2003 and 
2009 who had colorectal surgery using the SEER-linked Medicare database. T2DM was 
identified using the ICD-9-CM (International Classification of Diseases, 9th Revision, 
and Clinical Modification) codes during the 12-months prior to incident diagnosis 
of CRC. CRC surgery was identified with procedure codes for colon resection, rectal 
resection, and other operations on the intestine including colostomy and ileostomy. If 
individuals with CRC had ICD-9-CM codes indicative of bowel perforation, peritonitis, 
or obstruction, they were considered to have emergency surgery. Chi-square tests 
and logistic regression were used to analyze the association between pre-existing 
T2DMand emergency surgery after adjustments for sex, race/ethnicity, age, cancer 
site, stage, region, and office visits in the 12 months prior to incident cancer. RESULTS: 
Unadjusted rates of emergency surgery were significantly lower among CRC patients 
with pre-existing T2DM compared to CRC patients without diabetes (9.8% vs.11.4%). 
This association, however, was not significant in adjusted analyses. CRC patients 
with highest number of annual office visits were significantly less likely than CRC 
patients with lowest number of annual office visits to receive emergency surgery 
(AOR= 0.69; 95%CI= 0.61, 0.78). Other risk factors for emergency surgery in CRC patients 
were old age (80-84 years: AOR= 1.15, 95%CI= 1.03, 1.29; 85 years and above: AOR= 1.41, 
95%CI= 1.26, 1.58), and late stage at diagnosis (regional stage: AOR= 2.14, 95%CI= 1.99, 
2.31; distant stage: AOR= 2.78, 95%CI= 2.54, 3.05). CRC patients with atherosclerosis 
were less likely to have emergency surgery compared to those without atherosclerosis 
(AOR= 0.89; 95%CI= 0.82, 0.97). CONCLUSIONS: Pre-existing T2DM was not associated 
with emergency surgery after controlling for a comprehensive list of risk factors.
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OBJECTIVES: NCCN guidelines recommend that non-metastatic colorectal cancer 
(CRC) patients receive a comprehensive work-up including detailed imaging studies. 
The purpose of this study was to evaluate physician concordance to NCCN guide-
lines in terms of the receipt of tests and procedures during the 6-month period prior 
to a patient’s CRC diagnosis. METHODS: A large integrated claims database span-
ning January 2008 to September 2013 was used to identify patients ≥ 50 years old 
diagnosed and treated for CRC. Patients were required to be continuously enrolled 
for ≥ 6 months pre- (baseline period) and ≥ 3 months post-diagnosis. Eligible patients 
were stratified into cohorts based on the occurrence and timing of metastatic (M) 
disease: no metastases (NM), ≤ 90 days (M1), and ≥ 90 days (M2) from initial diag-
nosis. Tests evaluated included disease-appropriate CT or MRI, ultrasound, blood 
and fecal screenings, baseline biopsy, CEA, endoscopy, PET-CT, proctoscopy, sig-
moidoscopy, and colonoscopy. RESULTS: There were 15,182 patients meeting study 
criteria, with 77.8% being NM, 11.2% M1, and 11.0% M2. Over 75% of patients had a 
health physical in the baseline period but only 43.3% received fecal or blood-based 
screenings. The most common invasive procedure was colonoscopy, occurring in 
9.6% of M1, 13.7% of M2, and 11.7% of NM patients. Less than 20% of NM patients 
(17.8%) received a chest, abdominal, or pelvic CT or MRI compared to 20.7% of M1 
and 33.8% of M2 patients. Twice as many M2 patients (30.9%) received a CEA test 
compared to 15.1% of M1 and 24.6% of NM patients. Biopsy, ultrasound (including 
endorectal), proctoscopy, and sigmoidoscopy were documented in less than 5% of 
all patients. CONCLUSIONS: In this population of CRC patients, concordance to 
NCCN guidelines was low, with NM patients receiving a lesser degree of complete 
work-up per guidelines compared with M patients.
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OBJECTIVES: While cancer registries such as SEER currently serve as the larg-
est source of cancer epidemiology, recent research (Cogle, et al., 2012) has sug-
gested that these registries may be underreporting AML due to methodological 
limitations. Using a claims-based algorithm, we estimated the incidence of acute 
myeloid leukemia (AML) in the < 65 year-old US population. METHODS: A retro-
spective analysis of claims was performed using 2010-2012 IMS Health LifeLink 
PharMetrics Plus (LifeLink), a longitudinal medical claims dataset comprised of 
adjudicated claims of > 150 million unique enrollees. LifeLink is representative of 
the US commercially-insured population aged ≤ 65. AML diagnoses were identified 
using ICD-9 codes and AML treatments were identified using CPT/HCPCS codes 
and ICD-9-CM infusion codes. Patients with ≥ 2 claims including AML diagnoses 
codes OR one AML medical claim and one AML treatment in 2012 were defined as 
prevalent AML patients. A sub-population of all prevalent AML patients without 
historical AML diagnoses or treatments during the prior two years were identified 
as new (incident) AML patients. Results were stratified by gender and age (< 18, 
18-39, 40-49, 50-59, 60-64 years). RESULTS: The overall 2012 incidence of the < 65 
population was 5.4 per 100,000 (95% CI: 5.2, 5.6), with incidence incrementally 
increasing with age (i.e., lowest in the < 18 cohort [3.2 per 100,000] and highest in 
the 60-64 cohort [12.3 per 100,000]). Incidence among males was slightly higher 
than among females, 5.7 (95% CI: 5.3, 6.0) and 5.2 (95% CI: 4.9, 5.5) per 100,000, 
respectively. Males 60-64 had the highest incidence rate, 13.5 per 100,000 (95% CI: 
11.7, 15.2). CONCLUSIONS: Our 2012 AML incidence estimates are substantially 
higher than published SEER estimates for the < 65 population: 5.4 per 100,000 vs. 
SEER’s 1.8 per 100,000, respectively. Thus, the current AML burden of disease may 
be underestimated, further justifying the need for earlier detection and more 
efficacious treatment options.
ethnicity disparities exist in the association between diabetes and pancreatic can-
cer. METHODS: In a retrospective cross-sectional study, community-dwelling and 
institutionalized Medicare beneficiaries aged 65 or over without health maintenance 
organization enrollment from the Medicare Current Beneficiary Survey (MCBS) from 
2001 to 2010 were included. The outcome of the study was pancreatic cancer; and the 
key explanatory variables were diabetes and race/ethnicity. Potential confounders 
considered included age, gender, education, marital status, income, residence area, 
body mass index (BMI), smoking status, Charlson comorbidity index (CCI), and use 
of preventive services. The International Classification of Diseases-9 codes were 
used to identify the outcome and explanatory variables from the Medicare Part 
A and B claims. Logistic regressions were performed to estimate the association 
between diabetes and pancreatic cancer. RESULTS: A total of 98,966 person-years 
of elderly Medicare beneficiaries were included in the analysis. After controlling 
for potential confounders, the association between diabetes and pancreatic can-
cer was statistically significant (odds ratio [OR], 3.15; 95% confidence interval [CI], 
2.07-4.77). Compared to non-Hispanic whites, non-Hispanic blacks (OR, 0.43; 95% CI, 
0.15-1.20) and Hispanics (OR, 0.78; 95% CI, 0.33-1.85) had similar risks of pancreatic 
cancer. CONCLUSIONS: This study found that diabetes is associated with pancreatic 
cancer in the elderly Medicare population. However, racial/ethnicity differences do 
not explain the association between diabetes and pancreatic cancer.
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OBJECTIVES: The burden of comorbid illness is known to be higher among lung cancer 
patients and it’s also shown to impact survival outcomes. However, the influence of 
comorbidity on in-hospital surgical outcomes among lung cancer patients remains 
unknown. Therefore, this study examined the effect of comorbidity on risk of post-
operative complications, prolonged hospitalization, and in-patient death among lung 
cancer patients following surgery. METHODS: A retrospective analysis of hospital 
discharge data from the 2011 Health Care Utilization Project - Nationwide Inpatient 
Sample (HCUP-NIS) database was performed. Discharges of patients who underwent 
surgery for lung cancer during 2011 were identified. Information about patients and 
hospitals characteristics were obtained. Comorbidities were identified and used to 
calculate Charlson comorbidity index score. Patients were then divided based on these 
scores into four groups: 0, 1, 2, and ≥ 3. Multivariate logistic regression analyses was 
used to examine risk adjusted association between comorbidity score and the study 
outcomes. RESULTS: We identified 19,564 patients’ discharges that meet our inclusion 
criteria. Compared to patients with no comorbid conditions, patients with one or more 
comorbid conditions saw a two-fold increase in the risk of post-operative complica-
tions (p< 0.001). The risk of prolonged hospitalization was also higher among patients 
with a comorbidity score of 1, 2, or ≥ 3, compared to patients with a comorbidity score 
of zero (p< 0.001). Higher comorbidity burden also increased the risk of in-patient 
death by three folds (p< 0.001). CONCLUSIONS: In-hospital outcomes among lung 
cancer patients following surgery are negatively impacted by presence of comorbid 
illness. Post-operative morbidity and mortality among these patients may be reduced 
if their comorbid conditions are managed effectively.
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OBJECTIVES: Some new cancer therapies are associated with prolonged patient 
survival; therefore, management of chronic comorbidities in cancer patients has 
become more important. We sought to measure the prevalence of lipid disorders, 
and other chronic comorbidities, among cancer patients admitted to U.S. hospitals 
over a 14-year period. METHODS: We utilized data from the U.S. National Hospital 
Discharge Surveys from 1996 to 2009. We limited the study to patients ≥ 18 years 
of age with a primary discharge diagnosis of lung, breast, prostate, or colorectal 
cancer (ICD-9-CM codes 162, 174, 185, and 153, respectively). Data weights were 
used to derive national estimates. The prevalence of diabetes (250), ischemic heart 
disease (410-414), heart failure (428), cerebrovascular disease (430-438), and lipid 
disorders (272) was calculated for each year and cancer type. RESULTS: Roughly 
6 million visits were represented over the 14-year study period (lung 2.1, breast 
1.3, prostate 1.3, and colorectal cancer 1.6 million). One-third of patients admit-
ted with cancer had at least one comorbidity, and 8% had at least two comor-
bidities over the entire 14-year study interval; however, the rates of comorbidity 
changed drastically over time—particularly for lipid disorders. Of the patients 
admitted with lung cancer in 1996, only 2% had lipid disorders, compared to 13% 
in 2009. Similar patterns were observed for those patients admitted with breast 
cancer (2% to 17%), prostate cancer (3% to 30%), and colorectal cancer (2% to 12%). 
Prevalence of diabetes and ischemic heart disease also increased, but to a lesser 
extent. CONCLUSIONS: Management of lipid disorders in patients with cancer 
has become increasingly important. U.S. studies focused on improving cancer 
mortality, as well as the rising costs of care, should increasingly take chronic 
conditions—particularly lipid disorders—into account.
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OBJECTIVES: To examine the association between pre-existing Type 2 Diabetes Mellitus 
(T2DM) and risk of emergency colorectal surgery among elderly patients with colo-
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(20%) doses (mean ages at first Pap and first dose: 17.8 and 15.6 years). Adjusted 
incidences of any cytological abnormality (events per 100 annual person-visits) 
ranged between 11.61 with zero doses and 9.10 with three doses. Incidence rate 
ratios (IRRs) versus zero doses were 0.91 (95% CI: 0.87-0.96), 0.83 (95% CI: 0.80-
0.87), and 0.76 (95% CI: 0.74-0.79) for one, two, and three doses, respectively. For 
histology-confirmed high-grade lesions (CIN2+), IRRs versus zero doses were 0.63 
(95% CI: 0.51-0.77), 0.68 (95% CI: 0.58-0.82), and 0.47 (95% CI: 0.40-0.55) with one, 
two, and three doses, respectively. CONCLUSIONS: HPV vaccination may substan-
tially reduce the risk of cervical abnormalities in real-world settings, even when 
vaccination is incomplete. Policy and clinical efforts should focus on encouraging 
eligible girls to initiate vaccination.
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OBJECTIVES: Over 50% of oncology drugs fail in Phase III clinical trials. It remains 
imperative to better define ways of predicting whether a drug will demonstrate 
benefits prior to embarking on Phase III clinical trials. This research aims to explore 
whether Overall Response Rates (ORRs) from Phase II trials can be predictive of 
Phase III trial outcomes. METHODS: Phase III data of any Non-Small Cell Lung 
Cancer (NSCLC) and Renal Cell Carcinoma (RCC) oncologic appraised by the FDA, 
or that had failed Phase III clinical trials, since 2002 was extracted along with its 
corresponding Phase II data. RESULTS: 28 oncologics were identified with both 
Phase II and III readouts (NSCLC: 18, RCC: 10) only 12 (43%) of which met their Phase 
III trial endpoint (NSCLC: 6/18 (33%), RCC: 6/10 (60%)). Phase II ORRs varied from 
0%-61% (mean 26%) and were comparable, on average, to those seen in their cor-
responding Phase III trials (29%). 7/10 (70%) drugs with Phase II ORRs > 30% met their 
primary endpoint vs. only 5/18 (28%) with ORRs ≤ 30%. This threshold is dependent 
on whether the Phase III trial is active or placebo-controlled. For active-controlled 
Phase III trials, 3/4 (75%) met their primary endpoint with Phase II ORRs > 42% vs. 
3/12 (25%) with ORRs ≤ 42%. For placebo-controlled Phase III trials, 3/3 approved with 
Phase II ORRs > 16% versus only 3/9 with ORRs ≤ 16%. CONCLUSIONS: The magni-
tude of ORRs seen in Phase II can be correlated with later Phase III trial success in 
NSCLC and RCC. A higher Phase II ORR threshold applies where comparative benefits 
need to be shown over an active comparator in Phase III as opposed to over placebo. 
Further research can better define if such thresholds apply to other tumor types 
and whether this threshold can predict future Phase III trial failures and successes.
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OBJECTIVES: Hydrophobicity is the most important determinant of toxicity of bile 
acids (BAs) and depends on the number, position and orientation of hydroxyl groups. 
Ursodeoxycholic acid (UDCA) is a hydrophilic dihydroxy BA, which is formed by 
7β -epimerization of chenodeoxycholic acid (CDCA) in the gut by intestinal bacteria. 
Unlike the other secondary BAs, UDCA exerts antiapoptotic effects by preventing 
oxidative stress. The aim of our study was to analyze the influence of stereochemis-
try of hydroxyl groups on antiproliferative activity of BAs. METHODS: Human colon 
adenocarcinoma HT-29 cells were used to assess the cytotoxicity of CDCA and UDCA 
using colorimetric MTT assay. In order to explain obtained results of MTT assay, 12 
molecular descriptors relevant to polarity, solubility and membrane transport were 
calculated from 3D structures of CDCA and UDCA using VolSurf+ software. RESULTS: 
Studied BAs displayed distinct degrees of cytotoxicity towards HT-29 cancer cells in a 
concentration-dependent manner. Concentrations of CDCA and UDCA that inhibited 
cell growth by 50% (IC50) were 19.6 μ M and 351.9 μ M, respectively. Oxidative stress 
is considered to be the most plausible mechanism of cytotoxicity of BAs, which is 
determined mostly by their hydrophobicity. Calculated molecular descriptor that may 
explain these distinct cytotoxic effects is amphiphilic moment (A), which is defined as 
a vector pointing from the centre of hydrophobic domain to the centre of hydrophilic 
domain. The vector length (5.62 of CDCA and 4.87 of UDCA) determines the ability of 
compound to permeate a membrane. This was additionally substantiated with the 
values of CACO2, SKIN and LgBB descriptors that indicate higher Caco-2 permeability, 
skin permeability and blood-brain barrier distribution of CDCA in comparison to 
UDCA. CONCLUSIONS: More pronounced antiproliferative activity of CDCA in com-
parison to UDCA was observed. We suggest that computational methods exploring the 
physicochemical properties of molecules may help in prediction of their cytotoxicity.
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OBJECTIVES: Rigorous critical appraisal of clinical trials to assess bias and chance 
effects, which can distort trial results, can help evaluate the validity of research find-
ings. In a pre-specified integrated analysis of three phase 3 pivotal trials in patients 
with bone metastases secondary to breast cancer, prostate cancer, and other solid 
tumors or multiple myeloma (N= 5,723), denosumab was reported to be superior to 
ZA for the prevention of SREs, with statistically and clinically significant differences. 
Delfini Group performed critical appraisals of the three individual pivotal trials and 
the integrated analysis. METHODS: Published trials (Lipton et al, EJC, 2012; Stopeck 
et al, JCO, 2010; Henry et al, JCO, 2011, Fizazi et al, Lancet, 2011) were analyzed along 
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OBJECTIVES: To determine for which cancers the largest clinical advancements have 
been made, and to examine the relative health benefits offered by cancer-related 
interventions. METHODS: We used the Tufts Medical Center Cost-Effectiveness 
Analysis Registry to identify cost-utility analyses (CUAs) pertaining to cancer-related 
interventions published from 2002 through 2012. We determined the number of 
CUAs published for each cancer type, and their geographic setting. We also reported 
average incremental quality-adjusted life-year (QALY) gain for the five most studied 
cancer types, and for each cancer type the type of intervention offering largest 
health gains. RESULTS: Of the 3,244 published CUAs, 569 (17%) pertained to cancer. 
CUAs were most often set in the United States (40%), followed by United Kingdom 
(15%), Canada (9%) and Netherlands (4%). The five most studied cancers were breast 
(n= 154, 28%), colorectal (n= 62, 11%), cervical (n= 49, 9%), lung (n= 47, 8%) and prostate 
cancer (n= 46, 8%), for which interventions yielded on average, 0.32, 0.32, 0.06, 0.21, 
0.22 QALY gains, respectively. Among the five most studied cancers, the largest QALY 
gains were found for tertiary prevention interventions (mean 0.3, standard deviation 
(SD) 0.4), e.g., pharmaceuticals and surgeries; followed by secondary prevention (0.2, 
SD 0.4), e.g., diagnostic imaging. We found primary prevention interventions offered 
the smallest QALY gain (0.03, SD 0.08), e.g., immunizations. For breast and cervical 
cancer, pharmaceuticals offered the largest QALY gains, for lung and colorectal 
cancers, surgeries offered the largest QALY gains; and for prostate cancer, diagnos-
tics offered the largest QALY gains. CONCLUSIONS: We found many more CUAs for 
some cancers than for others, and that cancer-related CUAs are most often set in 
the US. The magnitude of QALY gain varied by cancer type. Pharmaceuticals offered 
the largest QALY gains for two of the five most studied cancers, but for other cancer 
types, surgeries and diagnostic imaging offered the largest QALY gains.
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OBJECTIVES: Clinical evidence supports the use of everolimus-based therapy (EVE) 
and of fulvestrant monotherapy (FUL) among postmenopausal women with hor-
mone receptor-positive human epidermal growth factor receptor-2 negative (HR+/
HER2-) metastatic breast cancer (mBC) whose disease progressed on non-steroidal 
aromatase inhibitor (NSAI). However, direct evidence was lacking on the compara-
tive effectiveness of these agents. This study compared progression-free survival 
(PFS) between EVE and FUL in a real-world setting. METHODS: This retrospective 
chart review examined postmenopausal HR+/HER2- mBC patients in community-
based oncology practices who received EVE or FUL (index therapy) for mBC as first-
line, second-line, or third- or later-lines after NSAI. PFS from index therapy initiation 
was assessed and compared using Kaplan-Meier analysis and a Cox proportional 
hazards model adjusting for index therapy line and characteristics at mBC diagnosis 
and index therapy initiation. RESULTS: A total of 192 and 156 patients received EVE 
or FUL, respectively, in a quota-based sample. EVE patients were less likely to have 
bone metastases, more likely to have visceral metastases or to have received prior 
chemotherapy for mBC, and had a shorter duration from initiation of last adjuvant 
endocrine therapy to mBC diagnosis. No significant PFS difference was observed in 
the unadjusted analysis. After adjusting for baseline characteristics, EVE patients 
had significantly longer PFS compared to FUL patients (hazard ratio [HR] = 0.71, 95% 
CI [0.51, 0.99], p = 0.045). When stratified by treatment line, second-line and third- or 
later-line EVE patients had significantly longer PFS (second-line: HR = 0.52, 95% CI 
[0.29, 0.91], p = 0.023; third- or later-lines: HR = 0.48, 95% CI [0.24, 0.93], p= 0.031) than 
FUL patients of the same treatment line. CONCLUSIONS: Among postmenopausal 
women with HR+/HER2- mBC who progressed on NSAI, the use of EVE was associ-
ated with better PFS, particularly on second-, third- and later-lines of treatment.
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OBJECTIVES: Human papillomavirus (HPV) vaccines prevent infection with the 
most cancer-causing HPV types. However, many age-eligible girls do not initiate 
or complete the three-dose regimen. There is limited information on the mag-
nitude of protection provided by partial-vaccination. We sought to empirically 
estimate the effect of HPV vaccination by dose (0, 1, 2 or 3) on cervical abnormality 
rates in a screening cohort of privately-insured U.S. girls (N= 234,829). METHODS: 
We defined a cohort within the MarketScan Commercial Claims database that 
included 9-17 year-olds in 2007 (year of vaccine introduction) who began Pap 
screening during 2008-2013. Follow-up started at subjects’ first-ever Pap and 
ended at abnormality detection or censoring. Treatment group corresponded to 
doses received before the first screening. We used inverse probability of treatment 
weighting to adjust for birth year, age/year of first Pap and first dose, plan type, 
region, zipcode-level socioeconomic factors, and claims-based sexual risk proxies. 
Weighted pooled logistic regressions estimated the effect of dose level on abnor-
mality rates. RESULTS: Subjects received zero (63%), one (8%), two (9%), or three 
